Phase I multiple-dose trial of SP 333 in volunteers.
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2014
At a glance
- Drugs Dolcanatide (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Synergy Pharmaceuticals Inc
- 22 Oct 2014 Status changed from recruiting to completed.
- 28 Jan 2013 Planned number of patients changed to 64, as reported in a Synergy Pharmaceuticals media release.
- 24 Jan 2013 Status changed from planning to recruiting, as reported in a Synergy Pharmaceuticals media release.